“Big Sky Biomedical was founded to enhance early-stage innovation and development in some of the fastest-growing segments of healthcare, including neurovascular, structural heart, and regenerative medicine,” Egeland in a news release out today.
“I’m extremely excited to apply my scientific, medical, and commercial experience to our portfolio companies in a much broader and deeper capacity,” Egeland said. “Alongside our exceptional teams of engineers, scientists, operators, and physician partners, I look forward to addressing significant underserved patient populations and large unmet clinical needs through compelling and differentiated technologies.”
Founded by a group of medical device serial entrepreneurs in the cardiovascular space, Big Sky Biomedical describes itself as a highly specialized incubator focused on rapid, capital-efficient therapy development.
“Ryan brings extensive, cross-functional expertise to our nimble, capital-efficient companies,” said JC Sun, founding partner of the incubator. “With his guidance and operational involvement, not only am I very confident in our ability to execute in the near term, but am extremely bullish about Big Sky’s potential to streamline zero to one value creation, setting a new standard for accelerating next-level medical device design and development.”
Before his nearly five years at Cardiovascular Systems, Egeland spent half a decade as an executive at Medtronic. He received his medical degree from Harvard Medical School and was a Rhodes Scholar at the University of Oxford, where he completed his PhD and MBA.
St. Paul, Minnesota-based Cardiovascular Systems announced on March 4 that Dr. Jeffery W. Chambers is its new chief medical officer. Chambers served as the primary investigator for the Orbit II study — the pivotal trial supporting premarket approval for the use of orbital atherectomy in coronary arteries.